Co-Authors
This is a "connection" page, showing publications co-authored by JAMES C YAO and DANIEL M HALPERIN.
Connection Strength
7.300
-
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022 06 01; 8(6):904-909.
Score: 0.847
-
A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas. 2019 03; 48(3):381-386.
Score: 0.676
-
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply. Lancet Oncol. 2017 06; 18(6):e300.
Score: 0.599
-
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017 04; 18(4):525-534.
Score: 0.588
-
Future Directions in the Biology of Neuroendocrine Tumors. Pancreas. 2016 07; 45(6):783-5.
Score: 0.562
-
Clinical Trial Design in Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016 Feb; 30(1):209-17.
Score: 0.546
-
[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol. 2016 Feb; 12(3):313-21.
Score: 0.544
-
Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. J Clin Oncol. 2015 Sep 10; 33(26):2914-9.
Score: 0.529
-
A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annu Rev Med. 2015; 66:1-16.
Score: 0.500
-
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Apr 01; 31(4).
Score: 0.239
-
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747.
Score: 0.199
-
Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer. 2021 Jan 01.
Score: 0.192
-
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 01; 3(10):1335-1342.
Score: 0.153
-
What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2017 01 20; 35(3):265-267.
Score: 0.145
-
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015 Jun; 22(3):431-41.
Score: 0.129
-
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014 Aug 02; 14:561.
Score: 0.123
-
Artificial intelligence-augmented analysis of contemporary procedural, mortality, and cost trends in carcinoid heart disease in a large national cohort with a focus on the "forgotten pulmonic valve". Front Cardiovasc Med. 2022; 9:1071138.
Score: 0.056
-
Bioprosthetic valve monitoring in patients with carcinoid heart disease. Front Cardiovasc Med. 2022; 9:1072890.
Score: 0.055
-
A Systematic?Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics. 2021 11; 39(11):1271-1297.
Score: 0.050
-
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2022; 112(1):34-42.
Score: 0.048
-
Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology. 2021; 111(9):850-862.
Score: 0.047
-
Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas. 2019 Nov/Dec; 48(10):1373-1379.
Score: 0.044
-
Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas. 2019 04; 48(4):510-513.
Score: 0.043
-
Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Med Res Methodol. 2018 12 12; 18(1):169.
Score: 0.042
-
The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment. Oncol Lett. 2019 May; 17(5):4126-4132.
Score: 0.041
-
Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics. 2018 08; 36(8):1005-1013.
Score: 0.041
-
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 06; 16(6):693-702.
Score: 0.040
-
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol. 2018 Jun; 25(6):1709-1715.
Score: 0.040
-
Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget. 2017 11 21; 8(59):99541-99551.
Score: 0.038
-
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017 12; 22(12):1451-1462.
Score: 0.038
-
Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1? Clin Endocrinol (Oxf). 2017 Jun; 86(6):791-797.
Score: 0.037
-
Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2017 01; 21(1):155-163.
Score: 0.036
-
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
Score: 0.032